Matching articles for "Tukysa"
Issue 1670 · February 20, 2023 Free
In Brief: A Second Indication for Tucatinib (Tukysa) (online only)

The oral kinase inhibitor tucatinib ( Tukysa – Seagen) has received accelerated approval from the FDA for use in combination with trastuzumab (Herceptin) for treatment of adults with RAS wild-type human…

Med Lett Drugs Ther. 2023 Feb 20; 65(1670):e37-8 doi:10.58347/tml.2023.1670g
The oral kinase inhibitor tucatinib ( Tukysa – Seagen) has received accelerated approval from the FDA for use in combination with trastuzumab (Herceptin) for treatment of adults with RAS wild-type human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimens. Tucatinib was approved in 2020 for use in combination with trastuzumab and capecitabine ( Xeloda , and generics) for treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who received at least one prior anti-HER2-based regimen for metastatic disease.
Issue 1611 · November 16, 2020
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)

The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki (…

Med Lett Drugs Ther. 2020 Nov 16; 62(1611):182-4
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki ( Enhertu – Daiichi-Sankyo/AstraZeneca), an IV HER2-directed monoclonal antibody linked to the topoisomerase I inhibitor DXd, and tucatinib ( Tukysa – Seagen), an oral tyrosine kinase inhibitor.